Miltenyi Biotec B.v. Co., Kg

Miltenyi Biotec, Gmbh

Miltenyi Biotech Gmbh

Andrzej Dzionek

David William Buck

Juergen Schmitz

Andreas Bosio

Olaf Hardt

Dominik Eckardt

Martin Meyer

Jutta Kollet

Wing Leung

Rafijul Bari

Stefan Tomiuk

Iris Bürger

Markus Granzin

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

Chimeric antigen receptor specific for tumor cells

The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Chimeric antigen receptor specific for BDCA2 antigen

The present invention relates to polypeptides comprising a mutant human IgG, which mutant human IgGis capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing Fc&#x3b3;RIIb/c (CD32b), but not Fc&#x3b3;RIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgGwith a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgGis capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgGand than a wild-type human IgG, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.

Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

This invention provides a method of detecting BDCA-2 protein in a biological sample. The sample is combined with an antibody or antigen binding fragment under conditions where the antibody or fragment will bind to BDCA-2 protein in the sample to form a complex, which is detected by formation of complex with the antibody. BDCA-2 protein may be displayed on the surface of dendritic cells. Binding of the antibody may result in down-regulation of type 1 interferon production, down-regulation of Th1 immune responses, induction of intracellular Camobilization, and/or polarization of an immune response towards Th2.

Ligating BDCA-2 protein with BDCA-2 specific antibody for detecting or modulating dendritic cells

The application describes, inter alia, a method for isolating or enriching for dendritic cells from a mixture of human cells involving contacting cells in the mixture with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment binds BDCA-4+ dendritic cells, and separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture.

Method for isolating BDCA-4+ dendritic cells

The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

Growing community of inventors

Cologne, Germany

Andrzej Dzionek